ScreenPoint Medical
Overview
ScreenPoint Medical is a leading innovator in AI-driven solutions for breast cancer detection and diagnosis. Their flagship product, Transpara, is an enterprise-grade AI tool designed to assist radiologists in interpreting mammograms and digital breast tomosynthesis (DBT) images. By leveraging advanced deep learning algorithms, Transpara aims to improve the accuracy and efficiency of breast cancer screening programs.
Transpara integrates seamlessly into existing radiology workflows, working alongside radiologists to provide a ‘second read’ or to prioritize studies based on AI-identified suspicious areas. This can help reduce reading times, decrease recall rates, and potentially improve the early detection of breast cancer, ultimately benefiting patient outcomes.
The platform is built with a strong emphasis on clinical validation and regulatory compliance, holding multiple regulatory clearances globally. ScreenPoint Medical collaborates with leading healthcare providers and PACS vendors to ensure secure and effective deployment within diverse clinical environments, including integration with platforms like Microsoft for Healthcare.
Physicians evaluating Transpara will find a tool designed to augment their expertise, providing objective and consistent analysis of breast imaging studies. Its capabilities extend to both 2D mammography and 3D DBT, offering comprehensive support for modern breast imaging practices. The company offers demonstrations to showcase the tool’s capabilities and discuss integration possibilities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered breast cancer detection
- 2D mammography analysis
- 3D digital breast tomosynthesis (DBT) analysis
- Second-read assistance for radiologists
- Prioritization of suspicious cases
- Integration with PACS systems
- Enterprise-grade deployment
- Regulatory clearances (FDA, CE Mark, Health Canada, TGA)
Use Cases
- Breast cancer screening programs
- Radiologist workflow optimization
- Improving early detection rates
- Reducing recall rates
- Standardizing mammography interpretation
- Training and quality assurance in breast imaging
What Physicians Need to Know
Leverage Transpara's risk stratification to prioritize your workload, focusing on 'Elevated' and 'Intermediate' risk cases. Trust the high negative predictive value (99.97%) of 'Low Risk' cases to expedite their review, thereby improving efficiency and reducing cognitive load. Integrate Transpara's findings, including region-based scores and overall exam scores, into your diagnostic process for a 'second pair of eyes' to enhance confidence and detection. Utilize the temporal comparison feature to track findings across prior mammograms for more effective longitudinal comparisons. Remember that Transpara is a decision support tool, and your clinical judgment remains central to all patient management decisions.
Transpara is designed for broad compatibility and integrates seamlessly with various clinical ecosystems. It is available through platforms like Aidoc's aiOSu2122, Microsoft's Precision Imaging Network, and Ferrum Health's Model Hub, simplifying deployment and providing a unified interface for AI results. It also integrates with reporting systems such as Ikonopedia. The solution is vendor-agnostic, working with any acquisition gantry and readable in any preferred reading environment, ensuring flexibility within existing infrastructure.
Details
| Category | Clinical Decision Support & Reference, Oncology AI, Radiology & Imaging AI |
| Pricing | Unknown — unknown |
| Deployment | Cloud-enabled access through Precision Imaging Network (Microsoft for Healthcare), integrates into PACS and reading workflows via medical-imaging (DICOM) pipelines, on-premise installations. |
| API Available | Yes |
| Target Size | Hospitals, clinics, and breast screening programs. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Cleared AI-estimated Transpara is FDA-cleared (K241831 and K232096) and CE (0344) certified for 2D and 3D mammography. The latest version, Transpara 2.1, is compatible with breast density options (BIRADS and volumetric) and temporal comparison, allowing analysis of suspicious areas against up to three prior exams over six years. Transpara is intended for use as a concurrent reading aid for physicians interpreting screening FFDM and DBT exams, to identify regions suspicious for breast cancer and assess their likelihood of malignancy. |
| GDPR | Yes AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Breast Imaging, Oncology, Radiology |
Social Proof
| Customers | Over 30 countries and 13 million mammograms processed. Over 200 healthcare facilities in more than 25 countries. Selected by 40% of the 2025 US News and World Report's Top 20 Best Hospitals Honor Roll recipients. |
| Notable | unknown |
What the Web Says
ScreenPoint Medical is a Dutch company specializing in AI-powered software for medical image analysis, primarily focusing on breast cancer detection with its flagship product, Transpara. The software is FDA-cleared and CE-marked and aims to assist radiologists in reading mammograms, improving detection rates, and reducing workload. Numerous studies and physician testimonials highlight its effectiveness in increasing cancer detection and enhancing workflow efficiency.
Overall: PositiveStrengths
- Increases cancer detection rates, with studies showing up to a 29% increase without increasing false positives.
- Reduces radiologist workload and reading time significantly, by as much as 44% in some studies, by prioritizing low-risk cases for expedited review.
- Acts as a 'second pair of eyes' for radiologists, improving confidence and consistency in identifying subtle abnormalities.
- Supported by a large body of clinical evidence, with over 55 peer-reviewed publications.
- Integrates prior imaging data to boost performance and improve clinical workflows.
- Effective across diverse patient populations, regardless of ethnicity, age, BMI, and breast density.
Limitations
- Some initial concerns about potential overdiagnosis with higher cancer detection rates, although subtype analysis in studies has been favorable.
- Radiologists may still need strategies to manage patient recall associated with intermediate-risk cases identified by the AI.
- Limited independent user reviews available on platforms like G2 and Capterra specifically for ScreenPoint Medical, making it difficult to gauge broader user sentiment outside of published studies and company-provided testimonials.
- The technology requires FDA review and approval for significant algorithm or functional updates.
- Some radiologists are naturally cynical about new technologies claiming to revolutionize the field and require clear, tangible value.
Based on reviews from: Vertex AI Search, The Lancet Digital Health, AuntMinnie.com, Indeed.com, Reddit, G2.com, Capterra.com, YouTube
Last updated: 2026-08-06
Ratings & Reviews
Rate ScreenPoint Medical
Press & Coverage
Videos
Product demos, reviews, and walkthroughs for ScreenPoint Medical.
